Balmer Paul, York Laura J
Senior Medical Director, Pfizer Vaccines Medical Development and Scientific/Clinical Affairs, Pfizer Inc., 500 Arcola Road, Collegeville, PA, USA.
Vice President, Global Meningococcal Vaccines, Pfizer Vaccines Medical Development and Scientific/Clinical Affairs, Pfizer Inc., 500 Arcola Road, Collegeville, PA, USA.
Ther Adv Vaccines Immunother. 2018 Jun 21;6(3):49-60. doi: 10.1177/2515135518781757. eCollection 2018 May.
is a major cause of meningitis and septicemia globally. Vaccines directed against serogroup B (MenB) have been used to control sporadic and sustained disease in industrialized and non-industrialized countries. Early outer membrane vesicle (OMV) vaccines effectively reduced MenB disease in countries such as Norway, New Zealand, and France; however, these vaccines were highly specific for their targeted outbreak strain, did not elicit a durable immune response, and were ineffective for widespread use due to the diversity of MenB-disease-causing isolates. Recently developed recombinant protein-based MenB vaccines that target conserved surface proteins have the potential to induce a broader immune response against the diversity of disease-causing strains. Given the deleterious consequences and sporadic nature of MenB disease, the use of optimal vaccination strategies is crucial for prevention. Reactive vaccination strategies used in the past have significant limitations, including delayed implementation, substantial use of resources, and time constraints. The broad coverage potential of recombinant protein-based MenB vaccines suggests that routine use could result in a reduced burden of disease. Despite this, routine use of MenB vaccines is currently limited in practice.
在全球范围内是脑膜炎和败血症的主要病因。针对B群脑膜炎奈瑟菌（MenB）的疫苗已被用于控制工业化国家和非工业化国家的散发性和持续性疾病。早期的外膜囊泡（OMV）疫苗在挪威、新西兰和法国等国家有效降低了MenB疾病；然而，这些疫苗对其靶向的暴发菌株具有高度特异性，不会引发持久的免疫反应，并且由于引起MenB疾病的分离株的多样性而无法广泛使用。最近开发的针对保守表面蛋白的基于重组蛋白的MenB疫苗有可能针对致病菌株的多样性诱导更广泛的免疫反应。鉴于MenB疾病的有害后果和散发性，采用最佳疫苗接种策略对于预防至关重要。过去使用的反应性疫苗接种策略有重大局限性，包括实施延迟、资源大量使用和时间限制。基于重组蛋白的MenB疫苗的广泛覆盖潜力表明，常规使用可能会减轻疾病负担。尽管如此，MenB疫苗的常规使用目前在实践中受到限制。
